

Drug and Therapeutics Committee – Minutes – Confirmed

Date / Time	Thursday 11 th November 8:15am – 9:30am
Venue	Webex
Chair	Prof A Morice, Chair, Professor of Respiratory Medicine
Notes / Action Points	Jane Morgan
Quorate: Yes / No	Yes
Attendance	Prof M Lind, Vice Chair, Professor of Oncology, HUTH Mr K McCorry, Medicines Optimisation Pharmacist, NECS Miss J Morgan, Professional Secretary, Principal Pharmacist – Formulary HUTH Dr O Ogunbambi, Consultant Rheumatologist, HUTH Prof T Sathyapalan, Consultant Endocrinologist, HUTH Ms J Goode, Chief Pharmacist, HUTH Mr P O'Brien, Deputy Chief Pharmacist, HUTH Mr R Kapur, Consultant Vascular Surgeon, HUTH Dr S Raise, GP Prescribing Lead, ER CCG
Apologies	Dr B Ali, GP Prescribing Lead, Hull CCG Dr H Klonin, Consultant Paediatrician, HUTH Mr A Dawood, Consultant Anaesthetist, HUTH Dr A Samson, Consultant Infectious Diseases, HUTH
Guests	Dr Antonio Ramirez, Deputy Chief Pharmacist, HUTH

Agenda No	Item	Discussion	Decision Made	Action	Lead	Due Date	Progress /Date Closed
2021.11.01	Apologies	As above					
2021.11.02	Declarations of Interest	None					
2021.11.03	Minutes of the previous meeting	Approved,	Update minutes	JM to update	JM	11/21	
			Update action tracker	JM to update	JM	11/21	
2021.11.04	Action Tracker	NICE Guidance JM to discuss with Dr Zaman TA681 Baricitinib for treating moderate to severe atopic dermatitis. Dr Zaman confirmed will use baricitinib as per TA	Action Complete	No further action	JM		11/21
		Dissemination of Information Across All Healthcare Groups /Providers No issues escalated during 6 month trial. To continue.	Continue to escalate via pharmacy teams	Review in 6 months	JM	5/22	
		Clinical Guidelines: Biologics and Small Molecules in Inflammatory Bowel Disease Guideline Antonio Ramirez joined the meeting to discuss the ustekinumab meeting with Prof. Sebastian, Dr Ananthansayanam and Dr Saleh. Prof Sebastian has agreed to de-escalate patients and there is a plan to give further support to the IBD team. There was extensive discussions around the issues identified and what was agreed in the meeting. KMc requested that the usekinumab report be shared with D&T and the CCGs. AM to write to Prof Sebastian to request updated guideline	Share ustekinumab report with D&T committee and request sharing via commissioners. To request updated guideline in line with commissioning	AM to write letter/ JM to add report to D&T	AM/JM	1/22	
		AOB - Hydroxychloroquine for Rheumatoid arthritis Minutes and action tracker updated. JM and OO met, Mr Vize has seen Harrogate guidance and would like to see if can be commissioned. JM	Check Harrogate pathway	JM to send Harrogate	JM	12/22	

Agenda No	Item	Discussion	Decision Made	Action	Lead	Due Date	Progress /Date Closed
		<p>to share Harrogate/West Yorkshire Care Partnership guidance with OO and JM to check how it fits with current Royal College guidance.</p> <p>Tracker – Intranasal analgesia guideline AM written to Dr Herrieven</p> <p>New Product Requests Bimekizumab JM updated formulary, AM written to applicant.</p> <p>New Product Requests AM to write to applicants</p> <p>ARIA Forms JM to update formulary</p> <p>Clinical Guidelines - Tolvaptan JM informed author, now using a new manufacturer so JM to update guideline to reflect current brand</p> <p>Clinical Guidelines – Ronapreve® JM updated pathway and information requested</p>	<p>Action complete</p> <p>Action complete</p> <p>Action complete</p> <p>Action complete</p> <p>JM to update</p> <p>Action complete</p>	<p>pathway to OO</p> <p>No further action</p> <p>No further action</p> <p>No further action</p> <p>No further action</p> <p>No further action</p> <p>No further action</p>	<p>AM</p> <p>JM/AM</p> <p>AM</p> <p>JM</p> <p>JM</p> <p>JM</p>		<p>11/21</p> <p>11/21</p> <p>11/21</p> <p>11/21</p> <p>11/21</p> <p>11/21</p>
2021.11.05	New Product Requests	<p>New Product Requests</p> <ul style="list-style-type: none"> Dienogest (endometriosis) – Mr J Tibbott/ Mr Phillips JM discussed evidence presented for this therapy for endometriosis. This is a licensed drug, which could be potentially used in primary care. KMc requested that a pathway be drafted for primary care to clarify place in therapy. Application approved and pathway to be requested for HERPC. Delstrigo® - Doravirine, Tenofvir DF, Lamivudine – Miss O'Keeffe Doravirine – Miss O'Keeffe Infectious diseases have requested doravirine is available as per the NHSE commissioning statements and regional 	<p>Approved</p> <p>Approved</p> <p>Approved</p>	<p>AM to write to applicants JM to update formulary</p>	AM/JM	12/21	

Agenda No	Item	Discussion	Decision Made	Action	Lead	Due Date	Progress /Date Closed
		<p>guidance. This is both as a single agent (which will be used in combination with other agents and as a combination with tenofovir and lamivudine. Approved as per NHSE commissioning and regional guidance</p> <ul style="list-style-type: none"> Inclisiran (TA733) – Dr Narayanan JM discussed this TA for inclisiran. Use approved as per TA. Lipid guidance needs updating for HERPC. <p>ARIA Forms</p> <ul style="list-style-type: none"> Zoledronic acid for osteoporosis Request from oncology to treat osteoporosis, restricted on formulary to metabolic bone disease and endocrinology. Oncology consultant Dr Aye to confirm it is OK for oncology to use. JM to request metabolic bone team guidance for zoledronic acid. TA705 Atezolizumab EAMs - Nivolumab in combination with chemotherapy in the treatment of oesophagus and stomach cancer Dabrafenib plus trametinib (interim COVID 19) Midostaurin TA523 	<p>Approved</p> <p>All approved</p>				
2021.11.06	NICE Guidance	<ul style="list-style-type: none"> TA735 Tofacitinib for treating juvenile idiopathic arthritis JM to confirm with NHSE if HUTH paediatric rheumatology centre TA736 Nivolumab for treating recurrent or metastatic squamous cell carcinoma of the head and neck after platinum-based chemotherapy On formulary for other TAs TA737 Pembrolizumab with platinum- and fluoropyrimidine-based chemotherapy for untreated advanced oesophageal and gastro-oesophageal junction cancer On formulary for other TAs TA738 Berotralstat for preventing recurrent attacks of hereditary angioedema Dr Gordins to complete application 	<p>Confirm if HUTH commissioned</p> <p>Noted</p> <p>Noted</p> <p>Application required</p>	<p>JM to request applications/ Aria forms.</p> <p>JM to request application</p>	JM	12/21	

Agenda No	Item	Discussion	Decision Made	Action	Lead	Due Date	Progress /Date Closed
		<ul style="list-style-type: none"> TA734 Secukinumab for treating moderate to severe plaque psoriasis in children and young people JM to confirm with Dr Zaman TA732 Baloxavir marboxil for treating acute uncomplicated influenza (terminated appraisal) TA733 Inclisiran for treating primary hypercholesterolaemia or mixed dyslipidaemia Discussed under agenda NG191 COVID-19 rapid guideline: managing COVID-19 TA740 -Apalutamide with androgen deprivation therapy for treating high-risk hormone-relapsed non-metastatic prostate cancer Not on formulary, aria form in progress TA741 - Apalutamide with androgen deprivation therapy for treating hormone-sensitive metastatic prostate cancer Not on formulary, aria form in progress TA739 - Atezolizumab for untreated PD-L1-positive advanced urothelial cancer when cisplatin is unsuitable On formulary for other indications NG206 - Myalgic encephalomyelitis (or encephalopathy)/chronic fatigue syndrome: diagnosis and management NG205 - Looked-after children and young people 	<p>Confirm with Dr Zaman</p> <p>Terminated appraisal Approved as per agenda item</p> <p>Noted Aria form needed</p> <p>Aria form needed</p> <p>Noted</p> <p>Noted</p> <p>Noted</p>	JM to e-mail Dr Zaman			
2021.11.07	MHRA Drug Safety Update	<p>Tofacitinib (Xeljanz ▼): new measures to minimise risk of major adverse cardiovascular events and malignancies JM to discuss getting list of patients, and cross check if any patients need reviewing by either gastroenterology or rheumatology</p> <p>Chloral hydrate, cloral betaine (Welldorm): restriction of paediatric indication JM to discuss with paediatric led pharmacist</p>	<p>Run report on usage and request review by specialist when needed</p> <p>To discuss with paediatric</p>	JM run report and check patients	JM	12/21	
2021.11.10	Minutes SMPC	Nil this month	Noted	No further action			
2021.11.09	Minutes from HERPC	Nil this month	Noted	No further action			

Agenda No	Item	Discussion	Decision Made	Action	Lead	Due Date	Progress /Date Closed
2021.11.10	Regional Medicines Optimisation Committees	<ul style="list-style-type: none"> • RMO North: draft guidance for dealing with requests for shared care from private providers, regional consultation • RMO SCF Consultation 6 	Noted	No further action			
2021.11.11	Clinical Guidelines	<ul style="list-style-type: none"> • Phenytoin guideline JM presented the update to the phenytoin guideline that had minor updates. • Prophylaxis and Treatment of Opioid-induced Constipation JM presented the new prophylaxis and treatment of opioid induced constipation; which has been prepared by the pain team. There are a number of minor amendments requested post SMPC, mostly relating to lack of consistency. 	<p>Approved</p> <p>Approved.</p>	<p>To feedback to author and add to CEPPDC agenda</p> <p>JM to inform author</p>	<p>JM</p> <p>JM</p>	<p>11/21</p> <p>11/21</p>	
2021.10.12	Correspondence received	Nil this month			JM		
2021.10.13	Chairs approvals	Doravirine – Dr Samson – patient didn't receive drug	No further action				
2021.10.14	Issues to escalate to Patient Experience and Clinical Effectiveness	Nil	No further action				
2021.10.15	Any Other Business	Nil					
	Date and Time of Next Meeting	Date: Thursday 9th December 2021 Time: 8.15am-9.30am Venue: WEBEX					